AQCell is designed to give that signal earlier.
Gene expression and pathway activity, from a compound, dose and time, and a cell’s baseline state.
Endpoints such as cell viability and hepatic endpoints, including drug-induced liver injury (DILI) risk, predicted alongside that biology.
Predictions are designed to trace back to biological pathways.
AQCell is designed to predict both chemical perturbations and functional endpoints.
Published perturbation models predict gene-expression changes.³ AQCell goes on to predict an endpoint.
A published analysis found that leading models make little use of drug features on new compounds.³ AQCell is designed to tell compounds apart.
Pathway-level predictions sit alongside the endpoint predictions, so results can be traced to biology.
Fine-tune AQCell on your own data inside your own environment.
Through the Virtual Cell Network, powered by Apheris, drug development teams can leverage federated learning to refine AQCell using their private biological datasets securely. Uncovering critical safety and efficacy signals earlier allows research groups to prioritize the right leads and make confident, data-backed assay decisions.4
Access AQCell through AWS Marketplace or Apheris Foundry.
Fine-tune on your own assays, or join the Virtual Cell Network to also train on data from across the industry. Your data never leaves your environment.
Continue fine-tuning as new results arrive.
Born at Alphabet in 2022, SandboxAQ brings computational chemistry, medicinal chemistry, biology, bioinformatics and AI together in one drug discovery team.
What partners say about SandboxAQ
With SandboxAQ’s platform, we increased the chemical exploration space from 250,000 molecules to 5.6 million. We identified candidate molecules faster and more efficiently with a hit rate 30 times greater.
This undruggable protein target has been by far our toughest drug discovery target to date. Having enabled medicinal chemistry on multiple promising starting points is an enormous achievement and extremely exciting.
SandboxAQ’s leapfrog technology could significantly impact both preclinical and clinical development of drugs, and we look forward to seeing how it could support us in delivering life-changing treatments to patients worldwide, faster.
